Skip to main navigation Skip to search Skip to main content

A Phase 1, Open label, Dose Finding Study to Assess the Safety and Tolerability of IMCgp100, a Monoclonal T Cell Receptor anti-CD3 scFv Fusion Protein in Patients With Advanced Malignant Melanoma

Project Details

Short titleA Phase 1, Open label, Dose Finding Study to Assess the Safety and Tolerability of IMCgp100, a Monoclonal T Cell Receptor anti-CD3 scFv Fusion Protein in Patients With Advanced Malignant Melanoma
StatusFinished
Effective start/end date31/01/11 → 31/03/21

Funding

  • Uhb Nhs Trust